Hematologic Malignancies Clinical Trials in Portland, Oregon

3 studies are recruiting for hematologic malignancies in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

    The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Providence Portland Medical Center ( Site 0051), Portland, Oregon
    Locations
    782 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT03486873 on ClinicalTrials.gov

  2. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage
    Not phased
    Ages
    Any age
    Site
    Oregon Health & Science University/Doernbecher Children's Hospital, Portland, Oregon
    Locations
    142 in total
    Run by
    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

  3. IVIG for Infection Prevention After CAR-T-Cell Therapy

    This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell the…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, Oregon
    Locations
    7 in total
    Run by
    Fred Hutchinson Cancer Center

    See if you can join NCT05952804 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.